Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
about
Targeting the tumor vasculature to enhance T cell activityVascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.Inhibition of tumors cell growth in osteosarcoma-bearing SD rats through a combination of conventional and metronomic scheduling of neoadjuvant chemotherapy.Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristineAnti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy.Evaluation of a UCMK/dCK fusion enzyme for gemcitabine-mediated cytotoxicity.Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1.The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.Metronomics: towards personalized chemotherapy?Dynamic contrast-enhanced MRI of the microenvironment of pancreatic adenocarcinoma xenografts.Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.Strategies for improving drug delivery: nanocarriers and microenvironmental priming.Role of vascular normalization in benefit from metronomic chemotherapy.Gemcitabine kills proliferating endothelial cells exclusively via acid sphingomyelinase activation.
P2860
Q27026329-4FB2B922-7F65-4F77-A999-4997CC8EBCADQ30469815-77B8D76D-469B-44E0-ABC1-7B5D46B87AE9Q30471456-77B910B7-6E4D-4B52-A872-4E97CF3D59B9Q30523830-2E40FCD5-DA43-4368-9C1A-4CD28E7DAA34Q33557868-8EE49D18-3BC6-4FF7-9EDA-AA6DD21BA8DFQ33866374-71CACB3E-DC7F-4EB4-86E9-BEDAC7C1394DQ34346752-DAD014AC-7FA5-46A5-A72F-64BEE5CF99CEQ35165488-39D56236-D18C-4E4F-B512-A90C22EAAB1AQ35613655-90CB2CB1-53A2-4FB6-AA11-AC998AA69A78Q36282739-C76318BA-DB7D-484A-B49B-C210C4A03D40Q36761584-862147F0-0098-4407-9F32-4F16D940F372Q38218923-0E0F2C48-613E-432D-B663-2405C0E68543Q38665197-34F4E23E-3C02-4E7F-95B4-08E9CA42FCC5Q38694772-F020AB80-71C1-4A80-9BB7-1D3F3BF3110EQ38968910-E92D8750-685B-49F8-8C28-C617A49AEDBAQ42318133-15021182-8F07-479D-AAA5-E623D91982EBQ53478020-8344ED34-84CD-4E44-82A4-CD9F133FDED2
P2860
Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Metronomic gemcitabine suppres ...... ncreatic ductal adenocarcinoma
@en
Metronomic gemcitabine suppres ...... creatic ductal adenocarcinoma.
@nl
type
label
Metronomic gemcitabine suppres ...... ncreatic ductal adenocarcinoma
@en
Metronomic gemcitabine suppres ...... creatic ductal adenocarcinoma.
@nl
prefLabel
Metronomic gemcitabine suppres ...... ncreatic ductal adenocarcinoma
@en
Metronomic gemcitabine suppres ...... creatic ductal adenocarcinoma.
@nl
P2093
P2860
P356
P1476
Metronomic gemcitabine suppres ...... ncreatic ductal adenocarcinoma
@en
P2093
A I Minchinton
A K Buczkowski
C H Scudamore
C-W A Chang
D T T Yapp
J A Flexman
J H E Baker
P2860
P2888
P356
10.1038/SJ.BJC.6605727
P407
P577
2010-06-08T00:00:00Z
P5875
P6179
1018693860